171 related articles for article (PubMed ID: 37351544)
1. Vestibular tissue changes following administration of intravaginal prasterone: a vulvoscopic open-label pilot study in menopausal women with dyspareunia.
Goldstein SW; Goldstein I; Kim NN
Sex Med; 2023 Jun; 11(3):qfad028. PubMed ID: 37351544
[TBL] [Abstract][Full Text] [Related]
2. Improvements to the Vulva, Vestibule, Urethral Meatus, and Vagina in Women Treated With Ospemifene for Moderate to Severe Dyspareunia: A Prospective Vulvoscopic Pilot Study.
Goldstein SW; Winter AG; Goldstein I
Sex Med; 2018 Jun; 6(2):154-161. PubMed ID: 29678557
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of fractional CO2 laser treatment to the vestibule: a randomized, double-blind, sham-controlled, prospective 3-site clinical study in women with vestibular pain.
Goldstein SW; Goldstein I; Kim NN; Kellogg-Spadt S; Murina F
J Sex Med; 2023 May; 20(6):800-812. PubMed ID: 36779572
[TBL] [Abstract][Full Text] [Related]
4. Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women.
Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Gilbert L; Martel C; Balser J
J Sex Med; 2014 Jul; 11(7):1766-85. PubMed ID: 24774442
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; BSc AB; Martel C; Vaillancourt M; Balser J; Moyneur É;
Menopause; 2018 Nov; 25(11):1339-1353. PubMed ID: 30358731
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Balser J; Moyneur É;
Menopause; 2016 Mar; 23(3):243-56. PubMed ID: 26731686
[TBL] [Abstract][Full Text] [Related]
7. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Archer DF; Labrie F; Bouchard C; Portman DJ; Koltun W; Cusan L; Labrie C; Côté I; Lavoie L; Martel C; Balser J;
Menopause; 2015 Sep; 22(9):950-63. PubMed ID: 25734980
[TBL] [Abstract][Full Text] [Related]
8. Treatment of moderate to severe dyspareunia with intravaginal prasterone therapy: a review.
Portman DJ; Goldstein SR; Kagan R
Climacteric; 2019 Feb; 22(1):65-72. PubMed ID: 30554531
[TBL] [Abstract][Full Text] [Related]
9. Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10μg estradiol on symptoms of vulvovaginal atrophy.
Archer DF; Labrie F; Montesino M; Martel C
J Steroid Biochem Mol Biol; 2017 Nov; 174():1-8. PubMed ID: 28323042
[TBL] [Abstract][Full Text] [Related]
10. Intravaginal 6.5 mg prasterone administration in postmenopausal women with overactive bladder syndrome: A pilot study.
Matarazzo MG; Sarpietro G; Fiorito D; Di Pasqua S; Ingrassano S; Panella MM; Cianci A; Caruso S
Eur J Obstet Gynecol Reprod Biol; 2021 Aug; 263():67-71. PubMed ID: 34167036
[TBL] [Abstract][Full Text] [Related]
11. Prasterone: A Review in Vulvovaginal Atrophy.
Heo YA
Drugs Aging; 2019 Aug; 36(8):781-788. PubMed ID: 31290076
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical staining with CD117 and PGP9.5 of excised vestibular tissue from patients with neuroproliferative vestibulodynia.
Drian A; Goldstein SW; Kim NN; Goldstein AS; Hartzell-Cushanick R; Yee A; Goldstein I
J Sex Med; 2024 Apr; 21(5):479-493. PubMed ID: 38521973
[TBL] [Abstract][Full Text] [Related]
13. Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.
Labrie F; Derogatis L; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Balser J; Moyneur É;
J Sex Med; 2015 Dec; 12(12):2401-12. PubMed ID: 26597311
[TBL] [Abstract][Full Text] [Related]
14. The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review.
Simon JA; Goldstein I; Kim NN; Davis SR; Kellogg-Spadt S; Lowenstein L; Pinkerton JV; Stuenkel CA; Traish AM; Archer DF; Bachmann G; Goldstein AT; Nappi RE; Vignozzi L
Menopause; 2018 Jul; 25(7):837-847. PubMed ID: 29870471
[TBL] [Abstract][Full Text] [Related]
15. Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause.
Labrie F; Archer DF; Martel C; Vaillancourt M; Montesino M
Menopause; 2017 Nov; 24(11):1246-1256. PubMed ID: 28640161
[TBL] [Abstract][Full Text] [Related]
16. An overview of dehydroepiandrosterone (EM-760) as a treatment option for genitourinary syndrome of menopause.
Holton M; Thorne C; Goldstein AT
Expert Opin Pharmacother; 2020 Mar; 21(4):409-415. PubMed ID: 31928093
[No Abstract] [Full Text] [Related]
17. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.
Labrie F; Archer DF; Bouchard C; Girard G; Ayotte N; Gallagher JC; Cusan L; Baron M; Blouin F; Waldbaum AS; Koltun W; Portman DJ; Côté I; Lavoie L; Beauregard A; Labrie C; Martel C; Balser J; Moyneur É;
Maturitas; 2015 May; 81(1):46-56. PubMed ID: 25771041
[TBL] [Abstract][Full Text] [Related]
18. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens.
Labrie F; Martel C; Bérubé R; Côté I; Labrie C; Cusan L; Gomez JL
J Steroid Biochem Mol Biol; 2013 Nov; 138():359-67. PubMed ID: 23954500
[TBL] [Abstract][Full Text] [Related]
19. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women.
Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Gilbert L; Martel C; Balser J
Menopause; 2009; 16(5):923-31. PubMed ID: 19424093
[TBL] [Abstract][Full Text] [Related]
20. Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner.
Labrie F; Montesino M; Archer DF; Lavoie L; Beauregard A; Côté I; Martel C; Vaillancourt M; Balser J; Moyneur E;
Climacteric; 2015; 18(6):817-25. PubMed ID: 26517756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
